Skip to main content

COVID 19 Updates from RheumNow

Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE

It is almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under emergency use authorization (EUA). The question still being asked is whether the vaccine is safe for people with lupus? 

More severe COVID-19 outcomes in African American, Hispanic individuals with SLE

Lupus is a disease that disproportionately affects minorities and patients of color. In the past worse disease activity, severity as well as outcomes have been described in African American and Hispanic patients.

RheumNow Podcast - ACR 2021 Rehash (the good stuff..)

The ACR 2021 meeting has concluded. Dr. Jack Cush recounts a few more great abstracts from this past week’s virtual meeting.

Abstract Numbers below:

Psoriatic arthritis

Can "Ultra-low" dose Rituximab work for RA?

At day 3 of ACR Convergence 2021, the REDO trial presented data in abstract 1443 in an oral presentation challenging how low we can go with rituximab for rheumatoid art

Day 4 Report from ACR21

My favorite three presentations from day 4 at ACR 2021 included the following:

Breakthrough Infections in Rheumatic Disease Patients

ACR21 – Day 3 Report

Hitting the home stretch, day 3 presentations were big! Here are a few of my favorites:

Secukinumab Efficacy in Enthesitis-Related and Juvenile Psoriatic Arthritis.

ACR21 Best Abstracts We Saw - Day 3 (Monday)

The third day of ACR 2021 took a big leap in online content.  Here is a compilation (with links) of presentations were the “ACRBest” as seen by our RheumNow faculty. 

ACR21 Best Abstracts - Day 2

The RheumNow faculty reporters have been scouring and reporting on the best abstracts from the ACR. Here is a sampling of their choice abstract presentations reported during ACR 2020 Day 2 (#ACRbest).

ACR21 Best Abstracts - Day 1

The RheumNow faculty have been glued to their monitors all day, watching video, and running down abstract presentations to find the best – several of these stood out as #ACRBests. Here is a listing of “Best” they saw on Day 1.

Opening Day Report

The opening of ACR2 Convergence was a hit for all who signed up and viewed in. The day included the presidential address by outgoing president Dr. David Karp (UT Southwestern) and a keynote talk and interview with Dr. Seema Yasmin (Stanford).

Outcomes of COVID-19 in Patients with Rheumatoid Arthritis

The COVID-19 pandemic has presented a global challenge. Patients with rheumatic diseases – requiring lifelong immunosuppressants— are at high risk for respiratory and viral infections.

ACR21 Previews from Creaky Joints

CreakyJoints will present 11 posters and two oral presentations at ACR 2021. Data was derived from their large patient database and Arthritis Power Research Registry.  COVID-19 research revealed significantly high levels of anxiety, anger, depression, and social isolation, which were linked to me


Love this COVID ARDS risk calculator put forth by @JYazdanyMD at #ACR21 for our patient's with Rheumatic Diseases. A wonderful resource in talking to our patients about vaccine necessity! @CleClinicMD
Emily Littlejohn @ELittlejohnDO ( View Tweet )
2 weeks 3 days ago
#ACR21 Late breaking #ACRambassador Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised Patients with Autoimmune or Inflammatory Rheumatic Diseases: A Retrospective Cohort Analysis from a U.S. Nationally-sampled EMR Data Repository

Marie Kuchynski MD @Doctorkuch ( View Tweet )

2 weeks 3 days ago
Reasons for COVID-19 vaccine hesitancy in rheumatology pts in southeast US based on survey study: 🔰Vaccine being “rushed” or “experimental” 🔰Safety of vaccine in the patients’ rheumatologic diagnoses 🔰Side effects 🔰Concern for Allergic reaction Abst#1589 #ACR21 @RheumNow
swethaann23 @swethaann23 ( View Tweet )
2 weeks 3 days ago
Factors Associated with Poor Vaccine Response in Rituximab: Dr. Yuzaiful Yusof (@Yuz6Yusof) discusses abstract #0437 presented at the #ACR21 annual meeting.
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 3 days ago
Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE from Dr. Yuz Yusof ( @Yuz6Yusof) It's almost a year since the Pfizer-BioNTech SARS-CoV-2 vaccine has been made available by the FDA under EUA. But is the vaccine safe for people with lupus?
Dr. John Cush @RheumNow ( View Tweet )
2 weeks 3 days ago
GRA @rheum_covid data presented by @mugartegil. African-American and Hispanic individuals with SLE have MUCH worse COVID-19 outcomes. Likely related socioeconomic and health disparities. Abstr#1933 #ACR21 @RheumNow
Richard Conway @RichardPAConway ( View Tweet )
2 weeks 3 days ago
🚫Infection risk after COVID vaccination: US database 536 954 Controls and 47 303 pts w/ RMDs 〽️BNT162b2 19 vs. 36/1000 〽️ mRNA-1273 16 vs. 33/1000 〽️Janssen 26 vs. 47/1000 Infections ⬆️ RA, SpA, SLE, SSc, Polymyositis #ACR21 #AbstL16 @RheumNow
2 weeks 3 days ago
#ACR21 #AbstrL17 In pts treated with Rituximab, arrange a 3rd primary dose ASAP regardless mRNA or vector #COVID vaccine. An RCT of N=60 pts who did not seroconvert after primary dose, overall 94% either seroconverted/new T-cell response @RheumNow #ACRBest
Md Yuzaiful Md Yusof @Yuz6Yusof ( View Tweet )
2 weeks 3 days ago
CH COVID 19 Poster Review Abst 0196 Jackson & colleagues performed double blind RCT of anakinra in patients with features of COVID-19 cytokine storm - Anakinra + GC did not significantly impact outcomes in patients with cytokine storm syndrome #ACR21 @RheumNow
Akhil Sood MD @AkhilSoodMD ( View Tweet )
2 weeks 3 days ago
Late breaking, but just in time! mRNA COVID-19 3rd dose in RTX pts, w/o Ab response post initial series. After 3rd dose many had ab response or T cell response. Extra vaccine full doses can protect RTX pts from COVID! AbsL17 #ACRbest #ACR21 @RheumNow
Dr. Rachel Tate @uptoTate ( View Tweet )
2 weeks 3 days ago